

L2039-USMP

DOCKET NO.: UPAP0013-100

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: **David B. Weiner et al.**

Serial No.: **09/980,762**

Examiner: **Ilia I. Ouspenski**

Filing Date: **September 3, 2002**

Art Unit: **1644**

Title: **MUTANT HUMAN CD80 AND COMPOSITIONS FOR AND METHODS OF MAKING AND USING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application, and appoint

☒ Practitioners at Customer Number: **34137**

PLACE CUSTOMER NUMBER BAR
CODE LABEL HERE

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the Correspondence Address for the above-identified application to:

☒ Practitioners at Customer Number: **34137**

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Respectfully submitted,

The Trustees of the University of Pennsylvania

Date: 9/30/05

By: [Signature]

Name:
Title:

**TIMOTHY J. RAYNOR
DIRECTOR, INTELLECTUAL PROPERTY
CENTER FOR TECHNOLOGY TRANSFER
UNIVERSITY OF PENNSYLVANIA**

L2039-USNP

DOCKET NO.: UPAP0013-100

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: David B. Weiner *et al.*

Serial No.: 09/980,762

Examiner: Ilia I. Ouspenski

Filing Date: September 3, 2002

Art Unit: 1644

Title: **MUTANT HUMAN CD80 AND COMPOSITIONS FOR AND METHODS OF MAKING AND USING THE SAME**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, **The Trustees of the University of Pennsylvania**, a not for profit corporation of the Commonwealth of Pennsylvania, states that it is:☒ the assignee of the entire right, title, and interest of the above-identified application.

The extent (by, percentage) of its ownership interest is 50% in the patent application/patent identified above by virtue of either:

☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at **Reel 014206, Frame 0535** recorded on **June 24, 2003**.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

The Trustees of the University of Pennsylvania

Date: 6/6/05By: 

Name:

Title:

TIMOTHY J. RAYNOR
DIRECTOR, INTELLECTUAL PROPERTY
CENTER FOR TECHNOLOGY TRANSFER
UNIVERSITY OF PENNSYLVANIA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Weiner, Agadjanyan, Sekaly and Holterman**Serial No.: **09/980,762**Filing Date: **September 3, 2002**For: **Mutant human CD80 and compositions for and methods of making and using the same**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

Applicants hereby revoke all previous Powers of Attorney and hereby appoint:

☒ Practitioners at Customer Number: **34137** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Address all telephone calls and correspondence to:

Mark DeLuca
COZEN O'CONNOR, P.C.
1900 Market Street
Philadelphia PA 19103
Telephone No.: (215) 665-2000
Facsimile No.: (215) 665-2013

I am the:

- ☐ Applicant/Inventor.
- ☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Signature of Applicant or Assignee of Record

Respectfully submitted,

**INSTITUT DE RECHERCHES CLINIQUES DE
MONTREAL**Date: JULY 7, 2005By: Name: **Stephane Letourneau**Title: **Director Technology Transfer and Legal
Affairs**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Weiner, Agadjanyan, Sekaly and Holterman**Serial No.: **09/980,762**Filing Date: **September 3, 2002**For: **Mutant human CD80 and compositions for and methods of making and using the same**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant or Patent Owner, **INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL**, a **Canadian** corporation, of Application No. **09/980,762** filed on **September 3, 2002** and entitled **Mutant human CD80 and compositions for and methods of making and using the same**, states that it is:


- ☒ the assignee of the entire right, title, and interest; or
☐ an assignee of less than the entire right, title, and interest.

The extent (by, percentage) of its ownership interest is **25%** in the patent application/patent identified above by virtue of either:

- ☒ A copy of the assignment from the inventor(s) of the patent application identified above to Institute de Recherches Cliniques de Montreal, is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

INSTITUT DE RECHERCHES CLINIQUES DE MONTREALDate: JULY 7, 2005By: Name: **Stephane Letourneau**Title: **Director Technology Transfer and Legal Affairs**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Weiner, Agadjanyan, Sekaly and Holterman**Serial No.: **09/980,762**Filing Date: **September 3, 2002**For: **Mutant human CD80 and compositions for and methods of making and using the same**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

Applicants hereby revoke all previous Powers of Attorney and hereby appoint:

☒ Practitioners at Customer Number: **34137** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Address all telephone calls and correspondence to:

Mark DeLuca
COZEN O'CONNOR, P.C.
1900 Market Street
Philadelphia PA 19103
Telephone No.: (215) 665-2000
Facsimile No.: (215) 665-2013

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Signature of Applicant or Assignee of Record

Respectfully submitted,

**VALORISATION-RECHERCHE, SOCIETE EN
COMMANDITE**

Acting through its general partner Gestion Univalor,
societe en commandite, itself acting by its general
partner Univalor Inc.

Date: July 18th 2005

By: [Signature]
Name: **Marc Leroux**
Title: **President and Managing Director**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Weiner, Agadjanyan, Sekaly and Holterman**Serial No.: **09/980,762**Filing Date: **September 3, 2002**For: **Mutant human CD80 and compositions for and methods of making and using the same**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant or Patent Owner, **VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE**, a Canadian corporation, of Application No. **09/980,762** filed on **September 3, 2002** and entitled **Mutant human CD80 and compositions for and methods of making and using the same**, states that it is:

- ☒ the assignee of the entire right, title, and interest; or
☐ an assignee of less than the entire right, title, and interest.

The extent (by, percentage) of its ownership interest is **25%** in the patent application/patent identified above by virtue of either:

- ☒ A copy of the assignment from the inventor(s) of the patent application identified above to Universite de Montreal, and further a copy of the assignment from Universite de Montreal to Valorisation-Recherche, societe en commandite is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE

Acting through its general partner Gestion Univalor, societe en commandite, itself acting by its general partner Univalor Inc.

Date: July 16th 2005By: Name: **Marc Leroux**Title: **President and Managing Director**